Management of Plasma Cell Gingivitis by Two Surgical Techniques (PCG)

February 2, 2022 updated by: Yasser Mohamed Nabil Ahmed Khirat El Hadidi, Ain Shams University

Management of Plasma Cell Gingivitis by En-block Removal

Two surgical protocols for management of Plasma cell Ginigivitis; either by surgical enblock resection of cold laser resection

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Tow groups will be included the first will have six cases and second will have six cases. the first will be treated by ordinary surgical resection and second will be removed using soft tissue laser.

Study Type

Observational

Enrollment (Actual)

12

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Cairo, Egypt, 11757
        • Ain Shams University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patient suffering from plasma cell gingivitis

Description

Inclusion Criteria:

- patients suffering from the plasma cell gingivitis

Exclusion Criteria:

- Patient not eligible for maxillofacial surgery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
study group
Removal by soft tissue laser of the tumor
Device: soft tissue laser
Surgical laser used in excision purpose
control group
Removal by ordinary surgical scalpel

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
complete removal
Time Frame: one month
complete removal of lesion with safety margin
one month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ain Shams University

Investigators

  • Study Chair: mohamed diaa, professor, Ain Shams University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2022

Primary Completion (Actual)

January 10, 2022

Study Completion (Actual)

January 20, 2022

Study Registration Dates

First Submitted

January 23, 2022

First Submitted That Met QC Criteria

February 2, 2022

First Posted (Actual)

February 11, 2022

Study Record Updates

Last Update Posted (Actual)

February 11, 2022

Last Update Submitted That Met QC Criteria

February 2, 2022

Last Verified

February 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1232022

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

yes planning to share

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Plasma Cell Gingivitis

Clinical Trials on soft tissue laser

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe